JPWO2021172582A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021172582A5
JPWO2021172582A5 JP2022503384A JP2022503384A JPWO2021172582A5 JP WO2021172582 A5 JPWO2021172582 A5 JP WO2021172582A5 JP 2022503384 A JP2022503384 A JP 2022503384A JP 2022503384 A JP2022503384 A JP 2022503384A JP WO2021172582 A5 JPWO2021172582 A5 JP WO2021172582A5
Authority
JP
Japan
Prior art keywords
inhibitors
inhibitor
mek
aurk
wee
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022503384A
Other languages
English (en)
Japanese (ja)
Other versions
JP7761939B2 (ja
JPWO2021172582A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/007651 external-priority patent/WO2021172582A1/ja
Publication of JPWO2021172582A1 publication Critical patent/JPWO2021172582A1/ja
Publication of JPWO2021172582A5 publication Critical patent/JPWO2021172582A5/ja
Application granted granted Critical
Publication of JP7761939B2 publication Critical patent/JP7761939B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022503384A 2020-02-27 2021-03-01 抗がん剤をスクリーニングする方法及び膵がんの治療のためのキナーゼ阻害剤の組み合わせ医薬 Active JP7761939B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020032112 2020-02-27
JP2020032112 2020-02-27
PCT/JP2021/007651 WO2021172582A1 (ja) 2020-02-27 2021-03-01 抗がん剤をスクリーニングする方法及び膵がんの治療のためのキナーゼ阻害剤の組み合わせ医薬

Publications (3)

Publication Number Publication Date
JPWO2021172582A1 JPWO2021172582A1 (https=) 2021-09-02
JPWO2021172582A5 true JPWO2021172582A5 (https=) 2024-03-05
JP7761939B2 JP7761939B2 (ja) 2025-10-29

Family

ID=77491650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022503384A Active JP7761939B2 (ja) 2020-02-27 2021-03-01 抗がん剤をスクリーニングする方法及び膵がんの治療のためのキナーゼ阻害剤の組み合わせ医薬

Country Status (8)

Country Link
US (1) US20220387630A1 (https=)
EP (1) EP4115907B1 (https=)
JP (1) JP7761939B2 (https=)
KR (1) KR20220032607A (https=)
CN (1) CN114207437B (https=)
AU (1) AU2021226119B2 (https=)
CA (1) CA3151403A1 (https=)
WO (1) WO2021172582A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101896227A (zh) * 2007-12-12 2010-11-24 阿斯利康(瑞典)有限公司 包含mek抑制剂和极光激酶抑制剂的组合
CN102216775B (zh) * 2008-08-18 2014-04-16 马克斯·普朗克科学促进协会 对hsp90-抑制剂的易感性
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
CA2846496C (en) * 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US10660318B2 (en) * 2013-08-20 2020-05-26 Tosk, Inc. Non-mammalian RAS transgenic animal model
US9629851B2 (en) * 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
EP3076963A4 (en) * 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
US20190011435A1 (en) * 2015-12-30 2019-01-10 Icahn School Of Medicine At Mount Sinai Fly avatars for cancer and uses thereof
US10519113B2 (en) 2016-08-17 2019-12-31 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds, compositions, and methods of treating cancer
CN110678169A (zh) * 2017-03-31 2020-01-10 西雅图遗传学公司 Chk1-抑制剂与weel-抑制剂的组合
CA3057969A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy
JP2019206516A (ja) * 2018-05-23 2019-12-05 国立大学法人高知大学 膵癌細胞の浸潤転移抑制剤
US11633401B2 (en) * 2018-07-06 2023-04-25 Memorial Sloan Kettering Cancer Center Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
CN110295233B (zh) * 2019-07-08 2023-04-25 深圳开悦生命科技有限公司 DHX33基因作为Ras驱动的癌症分子靶点的应用

Similar Documents

Publication Publication Date Title
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
JOP20220008A1 (ar) مثبطات parp1
ZA201902053B (en) Pharmaceutical composition
MX2017013797A (es) Inhibidor de janus quinasa.
MX2021006552A (es) Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
ZA201902051B (en) Pharmaceutical composition
JOP20200336A1 (ar) طرق إعطاء مثبطات vmat2 معينة
MX2017009449A (es) Inhibidor jak.
PH12019502601A1 (en) Therapeutic compounds and compositions, and methods of use thereof
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX387725B (es) Composición farmacéutica.
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
FI3661510T3 (fi) Menetelmiä käyttäytymismuutosten hoitamiseksi
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
JP2020529995A5 (https=)
ECSP22036502A (es) Inhibidores del factor d del complemento para administraci?n oral
WO2021016256A3 (en) Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
CN109689652A (zh) 稠杂环类衍生物、其制备方法及其在医学上的应用
JP2014504636A5 (https=)
JP2018505218A5 (https=)
JPWO2021172582A5 (https=)
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
CO2023013780A2 (es) Una combinación que comprende un inhibidor de hdac6 específico y al menos un inhibidor del punto de control de ctla4
JPWO2022177029A5 (https=)
JP2019518052A5 (https=)